Cangrelor: A novel intravenous antiplatelet agent with a questionable future

Pharmacotherapy

Volumn 34, Issue 10, 2014, Pages 1061-1076

  Waite, Laura H ^a   Phan, Yvonne L ^a   Spinler, Sarah A ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

acute coronary syndrome; AR C69931MX; cangrelor; clopidogrel; P2Y12 inhibitor; percutaneous coronary intervention; prasugrel; ticagrelor

Indexed keywords

CANGRELOR; CLOPIDOGREL; CREATINE KINASE MB; PLACEBO; PRASUGREL; TICAGRELOR; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ANTIPLATELET EFFECT; ARTICLE; BLEEDING; BRIDGING THERAPY; CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); FORECASTING; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; TRENDS; UNITED STATES;

ADENOSINE MONOPHOSPHATE; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FORECASTING; HUMANS; INFUSIONS, INTRAVENOUS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; UNITED STATES;

EID: 84908235509     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1471     Document Type: Article

References (45)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-245.
2. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44-122.
3. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
6. Yusuf S, Zhao F, Meta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
7. Daiichi Sankyo announces phase 3 study results (PRASFIT-Elective Study) for the antiplatelet agent Prasugrel in Japan. Available from http://www.daiichisankyo.com/media-investors/media-relations/press-releases/detail/006002.html. Accessed May 15, 2014.
8. Eli Lilly and Company. Effient (prasugrel) package insert. Indianapolis, IN; 2013.
9. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006; 48: 931-8.
10. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
11. Bjelland TW, Hjertner O, Klepstad P, Kaisen K, Dale O, Haugen BO,. Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 2010; 81: 1627-31.
12. Penela D, Magaldi M, Fontanals J, et al. Hypothermia in acute coronary syndrome: brain salvage versus stent thrombosis? J Am Coll Cardio 2013; 61: 686-7.
13. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e652-735.
14. Bates ER, Lau WC, Angiolillo DJ,. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251-63.
15. Ueno M, Ferreiro JL, Angiolillo DJ,. Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther 2010; 8: 1069-77.
16. 12 receptor antagonist. J Clin Pharmacol 2010; 50: 27-35.
17. 12 antagonists. Semin Thromb Hemost 2005; 31: 195-204.
18. 2T receptor antagonist AR-C69931MX assessing safety, tolerability, and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85: 401-7.
19. Cangrelor Injection: FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM385234.pdf. Accessed February 12, 2014.
20. Chrono-log Corporation. Havertown, PA. VerifyNow PRU Test. Accumetrics, Inc. San Diego, CA. Available from http://www.chronolog.com. Accessed February 27, 2014.
21. VerifyNow PRU Test. Accumetrics, Inc. San Diego, CA. Available from http://www.accumetrics.com/products/verifynow-prutest. Accessed February 27, 2014.
22. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307: 265-74.
23. Franchi F, Rollini F, Muniz-Lozano A, Cho JR, Angiolillo DJ,. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther 2013; 11: 1279-91.
24. Jacobsson F, Swahn E, Wallentin L, Ellborg M,. Safety profile and tolerability of intravenous ARC69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 2002; 24: 752-65.
25. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS,. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121: 527-34.
26. 12 antagonists in an ex-vivo canine model. Thromb Res 2012; 130: 622-8.
27. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-29.
28. Cutlip DE, Windecker S, Mehran R, et al. Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-51.
29. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-16.
30. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
31. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-54.
32. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-41.
33. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303-13.
34. Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership. Plavix (clopidogrel) package insert. NJ: Bridgewater, 2013.
35. Ferraris VA, Saha SP, Oestrich JH, et al. 2012 Update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 2012; 94: 1761-81.
36. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-47.
37. Firstenberg MS, Dyke CM, Angiolillo DJ, et al. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. Heart Surg Forum 2013; 16: E60-9.
38. The Medicines Company. NDA 204598 Cangrelor for Injection Cardiovascular and Renal Drugs Advisory Committee Briefing Document. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM385236.pdf. Accessed February 12, 2014.
39. O'Riordan M,. FDA advisory panel votes no on approving cangrelor for PCI, bridge therapy. Available from www.medscape.com/viewarticle/820567. Accessed February 12, 2014.
40. The Medicines Company and MarketWired. The Medicines Company receives complete response letter from FDA requesting additional information for New Drug Application for its antiplatelet agent Cangrelor. Available from ir.themedicinescompany.com. Accessed May 7, 2014.
41. The Medicines Company to discuss the cangrelor update. Conference call May 1, 2014, at 0830 EST. Available from www.themedicinescompany.com. Accessed May 7, 2014.
42. Ndrepepa G, Neumann FJ, Richardt G, et al. Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. Circ Cardiovasc Interv 2013; 6: 354-61.
43. Garfinkle M, Lawler PR, Filion KB, Eisenberg MJ,. Red blood cell transfusion and mortality among patients hospitalized for acute coronary syndromes: a systematic review. Int J Cardio 2013; 164: 151-7.
44. Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013; 128: 1055-65.
45. Wiviott SD, Desai N, Murphy SA, et al. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies. Am J Cardiol 2011; 108: 905-11.